News | News By Subject | News by Disease News By Date | Search News

Liver or Gallbladder Disorder (misc) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Backed By Two Drug Powerhouses, GenSight Alum Launches New Biotech With $40 Million     5/4/2017
Gilead (GILD)'s $600 Million NASH Deal Finally Bears Fruit     4/26/2017
Look Out, Another Biotech Joins San Diego With $40 Million and Will Take on NASH     4/13/2017
Why Intercept Pharma (ICPT) Stock Jumped Nearly 10% On Friday After Providing Phase III Update     2/13/2017
Here's a Look at Allergan (AGN)'s Opportunity in NASH     1/16/2017
Bristol-Myers Squibb (BMY) Slams Down $100 Million to Make a Play Into NASH     11/14/2016
Gilead (GILD) Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report     11/2/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Massachusetts's Alnylam (ALNY) Falls After Stopping Development of RNAi Liver Disease Candidate ALN-AAT     10/3/2016
Galectin (GALT) Stock Craters After Phase IIa NASH Failure     9/28/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle     9/23/2016
Allergan (AGN)'s NASH Spree Continues With $50 Million+ Buyout of San Diego's Akarna Therapeutics     9/21/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year     9/16/2016
Tobira (TBRA) Stock Loses More Than Half Its Value After Phase IIb Trial Miss     7/25/2016
Intercept Pharma (ICPT)'s Liver Drug Wins Accelerated Approval by the FDA     5/31/2016

News from Around the Web
3 Major Variables That Could Derail The Dash To NASH     5/1/2017
Why Gilead (GILD) Should Pay Close Attention And Maybe Even Fear Allergan (AGN)'s NASH Program     4/25/2017
Liver Disease In Children Linked To Fructose Intake, Journal of Hepatology Reveals     2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters     2/14/2017
4 Small Biotechs That Could Give Gilead (GILD), Merck & Co. (MRK) Pfizer (PFE) Some Competition With NASH     10/7/2016
Citrus Fruits Could Help Prevent Obesity, Universidade Estadual Paulista Study     8/22/2016
Simple Blood Test Developed To Screen For Life-Threatening Liver Disease, Baylor College of Medicine Study     8/11/2016
A Colony Of Fat Mice Hidden In A Norfolk Lab Could Hold The Key For Liver Disease, Eastern Virginia Medical School Study     7/26/2016
Salem Nonprofit, Design That Matters, Creates Device To Treat Jaundice In Developing World     7/21/2016
Even Light Drinkers Should Watch For Fatty Liver Disease, Kumamoto University Study     5/25/2016
How Fasting Helps Fight Fatty Liver Disease, Helmholtz Zentrum Munchen Study     5/10/2016
How Waist Size Can Predict Liver Disease Risk, University Of Milan Study     4/18/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Biotech Startup Pandorum Technologies Creates India‚Äôs First 3D Printed Artificial Human Liver Tissue     12/29/2015
Could Image Mapping Offer Way To Do Noninvasive Liver Biopsies?     10/20/2015

Press Releases
Seventh Wave Laboratories Announces Partnership To Advance Liver Disease Research     5/19/2017
Albireo (ALBO) Announces Plans For Phase III Clinical Program Of A4250 In Patients With PFIC     5/18/2017
Endonovo Evaluating Therapeutic Potential Of Non-Invasive Electroceutical For Treatment Of Non-Alcoholic Steatohepatitis (NASH)     5/16/2017
Axim Biotech Clinical Study To Develop Bioequivalent Product To Marinol Listed On Clinicaltrials.Gov     5/15/2017
Novartis AG (NVS) Dives Deeper Into NASH With Exclusive Deal With Conatus Pharma     5/4/2017
Can-Fite BioPharma (CFBI)'s Liver Protective Drug Namodenoson Enters Phase II Trial For Treatment Of NAFLD/NASH     5/3/2017
Bristol-Myers Squibb (BMY)'s NASH Candidate Hits Main Goals In Mid-Stage Study     4/24/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial     4/24/2017
DURECT (DRRX) Announces Presentation Of Data From A Phase Ib Study Of DUR-928 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017     4/24/2017
Arbutus Biopharma (ABUS) Announces ARB-1467 Data Presentation At EASL     4/24/2017
Arrowhead Pharma (ARWR) Presents ARC-AAT Clinical Data At The International Liver Congress     4/24/2017
Eiger Biopharma Announces Additional Phase II Clinical Trial Results For Lonafarnib At The International Liver Congress 2017     4/21/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread     4/21/2017
Gilead (GILD) Presents Proof-Of-Concept Data For GS-0976 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017     4/21/2017
PROMETHERA Biosciences S.A./N.V. Presents Preclinical Data On Novel H2Stem Cell Therapy At EASL International Liver Congress     4/21/2017